Navigation Links
Study identifies drug resistance of CLL in bone marrow and lymph nodes
Date:12/6/2010

ORLANDO In research to be presented at the American Society of Hematology (ASH) annual meeting, investigators at Dana-Farber Cancer Institute in Boston offer a new explanation of why chronic lymphocytic leukemia (CLL) tends to recur in the lymph nodes and bone marrow after being cleared from the bloodstream by chemotherapy. Their findings will be reported during in an oral session on Monday, Dec. 6, at 4:45 p.m. in room 315 of the Orange County Convention Center.

To uncover the reasons for CLL's resilience in the marrow and lymph nodes, the researchers employed a technique called BH3 profiling, which had been devised by senior author Anthony Letai, MD, PhD, and his Dana-Farber colleagues in 2005. The technique makes it possible to identify cancer cells that are less likely to undergo mitochondrial apoptosis (a form of programmed cell death involving cell structures called mitochondria) because of alterations in the Bcl-2 family of proteins. These abnormalities can make such cells less susceptible to both standard chemotherapy and novel, targeted agents.

In the current study, Letai and his associates found that when CLL cells from patients were grown with non-cancerous support cells from the bone marrow and lymph nodes, the CLL cells were more resistant to apoptosis and hence harder to kill with treatment than were CLL cells from the bloodstream. Using BH3 profiling, they discovered that although circulating CLL cells were likely to die by mitochondrial apoptosis in response to treatment, CLL cells grown among non-cancerous cells were much less likely to die this way. The presence of these normal cells, known as stroma, apparently helped the CLL cells survive, despite receiving treatment that would otherwise have resulted in their death.

"We hope that by clearly identifying the ability of stromal cells to reduce the CLL cells' capability to undergo apoptosis, we can exploit strategies to selectively target the 'help' that stromal cells give to CLL cells," says Letai.


'/>"/>

Contact: Teresa Herbert
Teresa_Herbert@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. Teen Dating Violence is Common, Study Finds
2. Daily Sunscreen Use Does Protect from Melanoma, Study Finds
3. Kids Team Sports Often Lacking in Exercise, Study Finds
4. Penn study on skin formation suggests strategies to fight skin cancer
5. Gene Therapy Corrected Rare Bleeding Disorder: Study
6. Study finds family acceptance of LGBT youth protects against depression, substance abuse, suicide
7. U.S. Needs National Registry for Joint Replacement Devices: Study
8. Economist honored for study on impact of new cancer drugs on life expectancy
9. NIH study suggests that early detection is possible for prion diseases
10. Female Vets Much More Likely to Commit Suicide, Study Finds
11. Study Suggests Link Between Crohns Disease and PTSD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... ... Sosin, a founding partner at the law firm Sosin, Arnold & Schoenbeck, Ltd ... Illinois State Bar Association , in accordance with the organization’s rules of succession. ... state-wide election and served in that capacity for the past year prior to his elevation ...
(Date:6/28/2017)... ... June 28, 2017 , ... ... and financial planning assistance to clients in southern Montana, is announcing a focused ... Zoo Montana. , The outreach programs offered by Zoo Montana provide students with ...
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly 70 ... survey data released today by the American Society for Dermatologic Surgery ... the percentage of consumers considering a cosmetic medical procedure has doubled since 2013. ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Association’s SUNucate efforts, Louisiana became the sixth state to pass legislation which ... Governor John Bel Edwards’ signature, Louisiana joins the states of Alabama, Arizona, Florida, ...
(Date:6/27/2017)... NY (PRWEB) , ... June 27, 2017 , ... ... marketing experts to contribute to an upcoming case studies guidebook. This guidebook offers ... organization. , This book will include articles, case studies and how-to’s that fall ...
Breaking Medicine News(10 mins):
(Date:6/3/2017)... , June 3, 2017  Eli Lilly ... announced that results from the Phase 3 MONARCH ... (CDK)4 & 6 inhibitor, in combination with fulvestrant, ... with fulvestrant alone in women with hormone-receptor-positive (HR+), ... breast cancer who have relapsed or progressed after ...
(Date:5/30/2017)... May 30, 2017 Therapix Biosciences Ltd. (Nasdaq: ... in the development of cannabinoid-based drugs, today announced ... overview at three upcoming scientific and investor conferences ... Micro Invitational: ... Date:                     Wednesday, ...
(Date:5/23/2017)... , May 23, 2017  Leaf Healthcare, recognized ... medical devices for pressure ulcer prevention, will unveil ... Association of Critical Care Nurses, National Teaching Institute ... The Leaf Patient Monitoring System is ... the hospital environment.  The system seamlessly tracks patient ...
Breaking Medicine Technology: